(Q43525122)

24 November 2017

title

Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients (English)

1 reference

24 November 2017

0 references

13

C Robert

1 reference

24 November 2017

L Boussemart

1

1 reference

24 November 2017

E Routier

2

1 reference

24 November 2017

C Mateus

3

1 reference

24 November 2017

K Opletalova

4

1 reference

24 November 2017

G Sebille

5

1 reference

24 November 2017

N Kamsu-Kom

6

1 reference

24 November 2017

M Thomas

7

1 reference

24 November 2017

S Vagner

8

1 reference

24 November 2017

M Favre

9

1 reference

24 November 2017

G Tomasic

10

1 reference

24 November 2017

J Wechsler

11

1 reference

24 November 2017

L Lacroix

12

1 reference

24 November 2017

publication date

13 February 2013

1 reference

24 November 2017

1 reference

24 November 2017

volume

24

1 reference

24 November 2017

issue

6

1 reference

24 November 2017

page(s)

1691-1697

1 reference

Mutations of the BRAF gene in human cancer

24 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT015

Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT015

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT015

Overcoming metastatic melanoma with BRAF inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT015

Sorafenib-induced eruptive melanocytic lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT015

p16(INK4a) immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT015

Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT015

Autosomal-dominant calcium ATPase disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT015

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT015

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT015

Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT015

RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT015

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT015

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT015

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT015

Improved survival with MEK inhibition in BRAF-mutated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT015

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT015

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDT015

1 reference

24 November 2017

1 reference